Ultragenyx Pharmaceutical (LTS:0LIF) Accumulated Depreciation : $0.0 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ultragenyx Pharmaceutical Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Ultragenyx Pharmaceutical's quarterly accumulated depreciation increased from Sep. 2023 ($0.0 Mil) to Dec. 2023 ($-83.4 Mil) but then stayed the same from Dec. 2023 ($-83.4 Mil) to Mar. 2024 ($0.0 Mil).

Ultragenyx Pharmaceutical's annual accumulated depreciation increased from Dec. 2021 ($-50.0 Mil) to Dec. 2022 ($-63.4 Mil) and increased from Dec. 2022 ($-63.4 Mil) to Dec. 2023 ($-83.4 Mil).

Ultragenyx Pharmaceutical Accumulated Depreciation Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Accumulated Depreciation Chart

Ultragenyx Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

Get a 7-Day Free Trial

-25.99

-37.39

-50.04

-63.38

-83.40

Ultragenyx Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accumulated Depreciation	Get a 7-Day Free Trial															-	-	-	-83.40	-

Ultragenyx Pharmaceutical Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Ultragenyx Pharmaceutical Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultragenyx Pharmaceutical (LTS:0LIF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (LTS:0LIF) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

RARE:USA RARE:Mexico UP0:Germany

Address

60 Leveroni Court, Novato, CA, USA, 94949

Website

https://www.ultragenyx.com

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (LTS:0LIF) Headlines

No Headlines